Table 2.
Neoadjuvant treatment in gall bladder cancer
| Author, year [ref] | Design | Total patients | Baseline disease status | Regimen | Surgery done [%] | Clinical benefit rate [CR + PR + SD] | Median follow up | Survival |
|---|---|---|---|---|---|---|---|---|
| Aretxabala 1999 [50] | Prospective | 18 | Post simple cholecystectomy | EBRT 45 Gy with 5FU CI | 13 (72 %) | NA | 24 months | 38 % |
| Aretxabala 2004 [32] | Retrospective | 23 | Post simple cholecystectomy | EBRT 45 Gy with 5FU CI | 14 (60 %) | 43.8 months | 22 % | |
| Engineer 2011 [33] | Prospective | 14a | Locally advanced | EBRT 45 Gy with Gemcitabine | 6 (43 %) | 35 % | ||
| Sirohi 2013 [30] | Retrospective | 33 | Locally advanced | Gemcitabine-Platinum | 24 (72 %) | 82 % | 8.5 months | 31.7 months |
aUnpublished data from an ongoing study, based on personal communication
EBRT: external beam radiotherapy, 5FU: 5-fluorouracil, CR: complete response, PR: partial response, SD: stable disease